K20
Conditions
Interventions
Group 1: Patients, who have undergone an endoscopy of the upper gastrointestinal tract and were histologically diagnosed with Eosinophilic Esophagitis. Diagnosis of EoE will be established according t
128: 3-20 e6). Patients unconditionally will be treated according to current evidence-based european guidelines of the ESPGHAN society (European Society for Paediatric Gastroenterology Hepatology and
5: 335-58
Papadopoulou A et al., Journal of pediatric gastroenterology and nutrition. 2014
58: 107-18.). According to the clinical response, biosamples will be collected at different timepoints in order to compare intra- and interindividual changes. After diagnosis of EoE there are three di
Sponsors
Abteilung für pädiatrische Gastroenterologie und Hepatologie, Dr. von Haunersches Kinderspital, Klinikum der Universität München
Eligibility
Sex/Gender
All
Age
3 Years to 20 Years
Inclusion criteria
Inclusion criteria: • Patients with a histologically approved EoE or strong suspicion of EoE, who receive an upper endoscopy; • Hemoglobulin of at least Hb = 10 g/dl • Age > 3-20 years • Approval of patient (if > 6 years) or parents
Exclusion criteria
Exclusion criteria: Unfulfilled inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Following the assumption that T-cells play a crucial role in the multistep pathogenesis of EoE, we would like to characterize the tissue-resident T-cells in the Esophagus. In a prospective clinical study differences in the T-cell cohort will be analyzed longitudinally at the timepoint of diagnosis, after medical therapy and elimination diet. Aims and objectives: 1) Describing T-cell subpopulations and characterizing their function for eosinophilic inflammation and resolution in EoE. 2) Prospective characterization of the local T-cell receptor repertoire in the course of the disease. 3) Correlation of the T-cell immunobiology with local environmental factors like food allergens and the mucosa associated microbiome, as well as medical therapy and clinical Response (disease activity index, histopathology). | — |
Secondary
| Measure | Time frame |
|---|---|
| In the long run we aim at developing a novel therapeutic approach, which aims at T-cell immunoregulation and modulation of the gastrointestinal dysbiosis, using targeted alimentary or micbrobial interventions (e.g. nutrition, probiotics, selective antibiotics, microbial transfer). Additionally our objective is to identify novel biomarkers for diagnostic and therapeutic Response, which allow to stratify patients according to a targeted therapy. | — |
Countries
Germany
Contacts
Public ContactTobias Schwerd
Universitätsklinikum Einrichtung: Klinikum der Universität München, Dr. von Haunersches Kinderspital
Outcome results
None listed